Evidence map›Paper›PMID 42041735›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.

Selami Bayram, Bahadır Köylü, Maral Martin Mıldanoğlu, Mustafa Serkan Alemdar, Tahir Yerlikaya, Fatih Selçukbiricik, Ahmet Bilici, Ali Murat Tatli, Mustafa Ozdogan

Abstract readMulticenter Study
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Selami BayramDepartment of Medical Oncology, Memorial Antalya Hospital, 07025 Antalya, Turkey.ORCID 0000-0002-0930-5025
Bahadır KöylüDepartment of Internal Medicine, Division of Medical Oncology, School of Medicine, Koç University, 34450 Istanbul, Turkey.ORCID 0000-0002-4462-6393
Maral Martin MıldanoğluDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, 34810 Istanbul, Turkey.ORCID 0000-0002-4587-0726
Mustafa Serkan AlemdarDepartment of Medical Oncology, Medikal Park Antalya Hospital, 07160 Antalya, Turkey.ORCID 0000-0002-7663-6182
Tahir YerlikayaDepartment of Medical Oncology, Antalya State Hospital, 07070 Antalya, Turkey.ORCID 0000-0003-2212-1412
Fatih SelçukbiricikDepartment of Internal Medicine, Division of Medical Oncology, School of Medicine, Koç University, 34450 Istanbul, Turkey.
Ahmet BiliciDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, 34810 Istanbul, Turkey.
Ali Murat TatliDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, 34810 Istanbul, Turkey.
Mustafa OzdoganDepartment of Medical Oncology, Memorial Göztepe Hospital, 34634 Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAgedFemaleHumansMaleMiddle AgedMutationProto-Oncogene Proteins p21(ras)Retrospective StudiesTurkeyProto-Oncogene Proteins p21(ras)KRASmolecular profilingnext-generation sequencingoverall survivalpancreatic ductal adenocarcinomaprecision oncologyprogression-free survivalreal-world studyTP53tumor mutational burden

Identifiers

PMID42041735
PMCPMC13114962

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.